Stocks · News reference
Curis Announces First Five Patients Dosed In TakeAim CLL Study Of Emavusertib With Zanubrutinib; Reaffirms Initial Data In 5-10 Patients In December 2026
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Dow Surges 250 Points; M&T Bank Posts Upbeat Q3 Earnings
U.S. stocks mixed: Dow +0.48%, Nasdaq -0.65%, S&P -0.05%. Energy rose, tech fell, and M&T Bank beat Q3 estimates; oil eased, gold gained.
Curis Commences ~$8.5M Offering Of 16.666M Common Shares, Warrants At $0.51 Per Share
Curis, Inc. (Nasdaq: CRIS) ("Curis" or the "Company"), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today
Why Veea Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Veea jumps 34% after regaining Nasdaq compliance; Freight Technologies leads gainers, while Alignment Healthcare plunges 24% among premarket losers.